Tests blood and urine methods for detecting sarcoma
Checks blood and urine for signs of bone or soft tissue sarcoma.
Plain-language title generated from the registry record
Registry title: LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy and Spectroscopy-based Molecular Urinalysis in Sarcoma Patients
Key facts
- Where
- Charlotte and Winston-Salem, United StatesSee the 2 sites
Where in United States
- Levine Cancer InstituteCharlotte, United StatesTaking people
- Atrium Health Wake Forest Baptist Comprehensive Cancer CenterWinston-Salem, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Wake Forest University Health Sciences
- Trial code
- NCT06958107
- Record updated
- 21 October 2026
- Original description
The purpose of this research study is to see how well Low Pass Whole Genome Sequencing (LP-WGS) can detect circulating tumor deoxyribonucleic acid (ctDNA) in the blood of participants who have bone or soft tissue sarcoma (type of cancer). This study is also looking at a new technology called Rametrix® Molecular urinalysis (RMU). The study is using this technology to evaluate changes in the urine that may indicate the presence of disease or cancer.Read full original descriptionShow less
Prospective Clinical Evaluation of Circulating Tumor DNA Liquid Biopsy and Spectroscopy-based Molecular Urinalysis in Patients With Sarcoma
The purpose of this research study is to see how well Low Pass Whole Genome Sequencing (LP-WGS) can detect circulating tumor deoxyribonucleic acid (ctDNA) in the blood of participants who have bone or soft tissue sarcoma (type of cancer). This study is also looking at a new technology called Rametrix® Molecular urinalysis (RMU). The study is using this technology to evaluate changes in the urine that may indicate the presence of disease or cancer.
Inclusion: Written informed consent or assent when applicable from the participant, LAR, parent or legal guardian and HIPAA authorization for release of personal health information; All ages allowed; Suspected or confirmed disease (must meet one of the criteria below):; Suspected bone or soft tissue tumor concerning for sarcoma (pending confirmation of sarcoma diagnosis); OR; Suspected lipomatous mass concerning for ALT or WDLS with planned surgery; OR; Confirmed bone or soft tissue sarcoma meeting one of the criteria below:; Non-metastatic/Resectable sarcoma with either planned or currently receiving therapy; Metastatic or unresectable sarcoma, with planned or currently receiving therapy; Non-metastatic sarcoma under surveillance with no more than 1 year from completion of therapy.
Exclusion: none.